Dana-Farber Cancer Institute

Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.

Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.

Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.

AI-assisted scoping review of code sharing in clinical prediction model research

Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.

New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.

Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.

A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.

Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.

Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.

A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.

Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Magnolia Contreras, MSW, MBA, of Dana-Farber Cancer Institute, was honored with The Lemuel Shattuck Award for Significant Contributions to Public Health Practice.

A small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment

Studies in pancreatic and prostate cancer selected for ASCO’s Plenary Program.

A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.

Researchers are optimistic about epigenetic tools for studying the impact of environmental exposures on genes, but further investigations are needed before drawing conclusions on the causes of early-onset colorectal cancer.

Dana-Farber Cancer Institute announced a gift to support cancer prevention and establish the Larry and Susan Marx Chair for Early Detection.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Researchers used a genome-wide CRISPR knockout screen to pinpoint genes that help human AML cells avoid being engulfed by macrophages.

Kathleen Burns, MD, PhD, of has been elected as Fellow of the American Association for the Advancement of Science.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.